Barbara Lead (CEO) and Matthew Young (CTO) will be present at Biotech Showcase 2016 from Jan 11th-13th (https://lnkd.in/e7-gUTh) in San Francisco. To arrange to meet them you can contact us via our Contact page.
Oval Medical’s CEO, Ms Barbara Lead will be one of the panellists in the Industry Roundtable “Drugs, Delivery, and Patients – How Will We Bring It All Together in the New World?” at the Annual Meeting of the Controlled Release Society on Sunday July 26th. The panel discussion, moderated by Ms Debra Bingham (Partner at […]
Oval Medical’s partner Solize Corporation will exhibit and present at the InnoPack 2015 conference in Tokyo (April 22-24th) in conjunction with the CPhI event held at TokyoBigSight. Representatives from Oval and Solize will be present to demonstrate the Oval autoinjectors and collaboration opportunities. Oval Medical has been attending and exhibiting at a number of conferences […]
April 2015 Oval Medical completes Innovate UK (formerly The Technology Strategy Board) Smart Award Grant for development of manufacturing equipment for their novel container closure system. Oval Medical has developed bespoke sealing equipment for the drug container in collaboration with 3P Limited; this is a key manufacturing step for its leading edge auto injector. Commenting […]
March 2015 Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times. This equipment will form part of the manufacturing process for clinical […]
November 2014 Oval Medical received £25,000 to contribute to market research for its new, innovative epinephrine autoinjector for the treatment of anaphylactic shock. The incidence of allergies that can cause this serious and potentially fatal reaction is growing worldwide. Oval’s epinephrine autoinjector incorporates the same design philosophy as the first device being used for sumatriptan. […]
Press Release For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together in […]
Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]
Drug development pipelines are tending towards increasing numbers of injectable products, and amongst these an ever larger proportion are viscous biologics and sustained-release formulations.
Inclusive design has unique challenges because it aims to improve usability for a wide range of users. This typically includes people with lower levels of ability, as well as mainstream users. This paper examines the effectiveness of two methods that are used in inclusive design.